Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
85 participants
OBSERVATIONAL
2017-05-08
2018-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT05675319
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00530816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Relapsed Multiple Myeloma Participants
The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a diagnosis of relapsed MM \[according to 2014 International Myeloma Working Group (IMWG) criteria\] with 1 to 3 prior lines of therapy. (An induction regimen followed by autologous stem cell transplantation and single-agent maintenance therapy will be considered a single line of therapy.)
* Participants must have initiated a new line of induction therapy that includes a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 90 days prior to enrollment. A short course of corticosteroids is allowed prior to initiating the new line of induction therapy
* Must be willing and able to complete the protocol-required patient-reported outcome (PROs)
Exclusion Criteria
* Participant has a life expectancy of less than 6 months
* At the time of screening, participant is enrolled in an interventional clinical trial for MM using an anti-neoplastic agent that is not currently approved by the United States (US) Food and Drug Administration (FDA)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Scientific Affairs, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Scientific Affairs, LLC Clinical Trial
Role: STUDY_DIRECTOR
Janssen Scientific Affairs, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Mercy Research
Fort Smith, Arkansas, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
St. Bernard's Medical Center
Jonesboro, Arkansas, United States
CARTI
Little Rock, Arkansas, United States
Facey Medical Group
Mission Hills, California, United States
North County Oncology
Oceanside, California, United States
Ventura County Hematology Oncology Specialists
Oxnard, California, United States
James R. Berenson, MD Inc.
West Hollywood, California, United States
PIH Health Hospital
Whittier, California, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
University Cancer Institute (UCI)
Boynton Beach, Florida, United States
Southeast Florida Hematology Oncology Group
Fort Lauderdale, Florida, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Watson Clinic Llp
Lakeland, Florida, United States
Ocala Oncology Center
Ocala, Florida, United States
Piedmont Cancer Institute
Atlanta, Georgia, United States
Augusta University
Augusta, Georgia, United States
Gwinnett Hospital System, Inc
Lawrenceville, Georgia, United States
Nancy N. and J.C. Lewis Cancer & Research Pavillion -St. Josephs Candler Health System
Savannah, Georgia, United States
Ingalls Memorial Hospital Cancer Research Center
Harvey, Illinois, United States
Orchard Healthcare Research
Skokie, Illinois, United States
Baptist Healthcare Systems, Inc. d/b/a Baptist Health Floyd
New Albany, Indiana, United States
Physicians' Clinic of Iowa, P.C at PCI Main Building
Cedar Rapids, Iowa, United States
Commonwealth Hematology-Oncology, P.C.
Danville, Kentucky, United States
Hardin Memorial Hospital
Elizabethtown, Kentucky, United States
Kentucky Cancer Care
Hazard, Kentucky, United States
Oncology Associates of West Kentucky
Paducah, Kentucky, United States
West Kentucky Hematology-Oncology
Paducah, Kentucky, United States
Pontchartrain Cancer Center
Covington, Louisiana, United States
Tulane University Hospital & Clinics
New Orleans, Louisiana, United States
Mercy Medical Center
Baltimore, Maryland, United States
Meritus Center for Clinical Research
Hagerstown, Maryland, United States
Reliant Medical Group, Inc.
Worcester, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
MidMichigan Health Cancer Center
Midland, Michigan, United States
Providence Cancer Center
Southfield, Michigan, United States
St. Luke's Speciality Clinic
Duluth, Minnesota, United States
Singing River Health System
Pascagoula, Mississippi, United States
Trinitas Comprehensive Cancer Center
Elizabeth, New Jersey, United States
Southern Oncology Hematology Associates
Williamstown, New Jersey, United States
North Shore Hematology Oncology Associates, P.C.
East Setauket, New York, United States
Hudson Valley Hematology Oncology Associates
Poughkeepsie, New York, United States
Community Health Network
Rochester, New York, United States
Mid Ohio Oncology Hematology, DBA The Mark H. Zangmeister Center
Columbus, Ohio, United States
Dayton Physicians, LLC
Kettering, Ohio, United States
Good Samaritan Hospital Corvallis
Corvallis, Oregon, United States
Abington Memorial Hospital
Abington, Pennsylvania, United States
Lehigh Valley Health network (Oncology)
Bethlehem, Pennsylvania, United States
Hematology and Oncology Associates of NEPA
Dunmore, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Aria Health- Torresdale
Philadelphia, Pennsylvania, United States
Charleston Cancer Center
Charleston, South Carolina, United States
Carolina Blood and Cancer Care
Rock Hill, South Carolina, United States
Wellmont Blue Ridge Medical Specialists
Bristol, Tennessee, United States
Jackson Madison County General Hospital
Jacksonville, Tennessee, United States
Texas Oncology P A
Arlington, Texas, United States
Texas Oncology P A
Beaumont, Texas, United States
Texas Oncology P A
Denton, Texas, United States
Texas Oncology P A
Flower Mound, Texas, United States
Texas Oncology-Memorial City
Houston, Texas, United States
Texas Oncology P A
Paris, Texas, United States
Texas Oncology P A
Plano, Texas, United States
Texas Oncology P A
Tyler, Texas, United States
Texas Oncology P A
Waco, Texas, United States
Texas Oncology P A
Webster, Texas, United States
Texas Oncology P A
Wichita Falls, Texas, United States
Kadlec Clinic Hematology & Oncology
Kennewick, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NOPRODMMY4001
Identifier Type: OTHER
Identifier Source: secondary_id
CR108326
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.